Awakn Life Sciences
Awakn Life Sciences is a biotechnology company researching, developing, and delivering psychedelic therapeutics to better treat addiction. Awakn’s team consists of world leading chemists, scientists, psychiatrists, and psychologists who are advancing the next generation of psychedelic drugs and therapies to be used in combination.
NEO: AWKN
OTCQB: AWKNF
FSE: 954
IR Website: https://awaknlifesciences.com/investor-relations
Headquarters: United Kingdom
TALK TO MANAGEMENT
The Awakn Life Sciences management team is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.
Summary
Awakn is focused on researching, developing and delivering psychedelic therapeutics to better treat addiction - one of the biggest unmet medical needs globally. 20% of the adult population suffer with substance addictions, like alcohol, and many more hundreds of millions of individuals suffer with behavioural addictions, like gambling and compulsive sexual behaviour.
The incumbent industry and providers have limited success, take Alcohol Use Disorder (AUD) for example, it affects 400m globally, but there is a 75% relapse rate within 12 months of treatment. Despite this low success rate and low market penetration, addiction treatments (medicines) are worth US$19bn per annum globally and is forecasted to increase to US$31.5bn in 2027. The Addiction rehab and recovery industry is worth US140bn per annum.
This is an industry that is ripe for disruption.
Based on new research, Awakn’s drugs will target the brain circuits that drive addiction through multiple receptors, rather than single drug receptors. These circuits control the behavioral drivers of addiction. By focusing on circuit mechanisms rather than isolated receptors, Awakn’s approach has the potential to be effective in the treatment of both substance and behavioral addictions. This disruption allows the individual to escape from the repetitive addictive behaviors and thoughts, and in doing so engage with a psychotherapeutic process to enable lasting positive change.
-
5 patent families filed
-
2 more families in preparation covering multiple chemical series and clinical indications
-
A completed phase-IIa/b trial for Ketamine-Assisted Therapy to treat AUD of which Awakn has acquired the exclusive rights to. Planning to progress this to phase-III
-
A completed phase-IIa trial for MDMA as a treatment for AUD of which Awakn has acquired the exclusive rights to. Planning to progress this to phase-IIb
%20(1).png?width=1500&name=image002%20(1)%20(1).png)
World leaders in addiction and psychedelic research
-
Professor David Nutt – Chief Research Officer
-
Professor Celia Morgan – Head of Ketamine-assisted therapy
-
Dr. Ben Sessa – Chief Medical Officer
-
Paul Carter – Independent Non-Executive Director (Former CCO of Gilead sciences)
-
Steve Page – Independent Non-Executive Director (Former CEO of The Priory Group)
Investor Presentation
Recent News
Awakn Life Sciences Files Patent Application For A New Class Of Entactogen-Like Molecules To Treat A Broad Range Of Addictions
Jan 26, 2022
Awakn Life Sciences Signs MOU With MAPS
Jan 19, 2022
Awakn Announces Positive Results From Phase II A/B Clinical Trial
Jan 11, 2022
Awakn Life Sciences Expands World’s First Ketamine Study Beyond Gambling Disorder To Include Additional Behavioral Addictions
Jan 5, 2022
Awakn Announces Voluntary Lock-Up Agreement Extension With Management, Board Of Directors And Key Shareholders
Jan 4, 2022
Management Overview
Anthony Tennyson
Co-Founder and Chief Executive Officer
Anthony Tennyson is Chief Executive Officer at Awakn Life Sciences, a biotechnology company with clinical operations, developing and delivering psychedelic therapeutics (medicines and therapies) to better treat addiction.
Anthony is an experienced financial services industry executive with 10 years in international strategy, commercial leadership roles with Aon plc, and five years with Merrill Lynch and Bank of Ireland.
He holds an MBA in Strategy and Finance and an MSc in Technology both from UCD, Ireland’s top ranked business school.
Kate Butler
Chief Financial Officer
Kate is a Chartered Accountant with significant experience of both UK and US public companies. Kate has worked across a number of sectors including pharmaceuticals and natural resources. Most recently Kate has held senior positions at Vectura Group plc, a FTSE 250 specialist inhalation contract development and manufacturing organisation, and Gilead Sciences Inc, a research-based biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. Kate has extensive experience of building strong finance teams and processes, and growing companies in new markets.
Prof. David Nutt
Chief Research Officer
David is a psychiatrist and the Edmund J. Safra Professor of Neuropsychopharmacology in the Division of Brain Science, Dept of Medicine, Imperial College London. Here he uses a range of brain imaging techniques to explore the causes of addiction and other psychiatric disorders and to search for new treatments. He has published over 400 original research papers, a similar number of reviews and books chapters, eight government reports on drugs and 28 books, including one for the general public, Drugs: Without The Hot Air, that won the Transmission Prize in 2014.
He is currently the President of the European Brain Council and Founding Chair of Drug Science. Previously he has been president of the British Association of Psychopharmacology, the British Neuroscience Association, and the European College of Neuropsychopharmacology. He broadcasts widely to the general public both on radio and television. In 2010 The Times Eureka science magazine voted him one of the 100 most important figures in British Science, and the only psychiatrist in the list. In 2013 he was awarded the John Maddox Prize from Nature/Sense about Science for standing up for science.
Celia Morgan
Head of Ketamine Assisted Psychotherapy for Addiction
Celia is a Professor of Psychopharmacology at the University of Exeter in the United Kingdom.
Prof. Morgan completed her undergraduate degree and Ph.D at University College London (UCL) and completed a scholarship programme at Yale University. After competing her Ph.D Prof. Morgan worked at University of Melbourne as a visiting research fellow, returning to UCL for a fellowship and then Lectureship. She joined University of Exeter as a Senior Lecturer in 2013 and was given a Chair in Psychopharmacology in 2015.
Prof. Morgan also holds an Honorary Readership at University College London. Prof. Morgan is academic lead for both Exeter Translational Addiction Partnership (ETAP) and Ketamine for Reduction of Alcoholic Relapse (KARE).
Dr. Ben Sessa
Co-Founder and Chief Medical Officer
Ben has specialist training as a child and adolescent psychiatrist and is interested in the developmental trajectory from child maltreatment to adult mental health disorders, including adult addictions. Dr Sessa’s joint interests in psychotherapy, pharmacology and trauma have led him towards researching the subject of drug-assisted psychotherapy using psychedelic adjuncts. In the last 15 years he has been part of scientific and clinical studies administering LSD, psilocybin, ketamine, MDMA and DMT to patients and volunteers.
He is the author of psychedelic medical exploration books; The Psychedelic Renaissance (2012 and 2017) and To Fathom Hell or Soar Angelic (2015). He has recently completed research with Imperial College London exploring the world’s first MDMA-assisted therapy trial for the treatment of Alcohol Dependence Syndrome.
Alongside Prof. David Nutt, Ben has also been a long term advocate of drug policy reform in the UK; believing that current laws hamper research and increase, rather than reduce, the burden of problematic drug use on individuals and society.
James Collins
Chief Operating Officer
James is a senior business leader and mental health champion with 17 years of experience with Accenture Strategy, 7 years as MD, designing and delivering corporate, digital and operating model strategies.
James holds a BSc and MPhil in Psychology from University College London (UCL).
James has been appointed has COO of Awakn Life Sciences in January 2021.
Jonathan Held
Co-Founder & Chief Business Officer
Jonathan is a chartered professional accountant, with CFO level experience for private / public companies.
Jonathan has worked in a number of sectors including technology, biotech and natural resources, both domestic and international, and has been involved in numerous successful public market transactions including Initial Public Offerings, Reverse Takeovers and financings.
Risks & Disclosures
This communication is neither an offer to sell nor a solicitation of an offer to buy, nor a recommendation of any securities of the company mentioned herein.
Awakn Life Sciences (the “Company”) and its counsel have reviewed the content of this page as well as the accompanying presentation (“Company Presentation”) displayed on this page. To the best of its knowledge, the Company does not believe this content to be misleading or inaccurate in any material respect, nor does it believe there are any material omissions with respect to such content. The Company does not believe the contents of the page or the Company Presentation to contain any non-public material information.
Information and opinions presented in the Company Presentation are provided by the Company, and b2i digital makes no representation as to their accuracy or completeness. The information contained on this page is not intended to constitute any form of advice, and the information provided is not intended to provide a sufficient basis on which to make an investment decision. It is not investment research, nor does it constitute a research recommendation, as it does not constitute substantive research or analysis. This information is not to be relied upon in substitution for the exercise of independent judgment.
Information, opinions and estimates contained on this page or in the Company Presentation reflect judgments by the Company as of the original date of publication by the Company and are subject to change without notice. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance.
A complete description of the risks and uncertainties relating to the Company and its securities can be found in the company's filings with the U.S. Securities and Exchange Commission available for free at www.sec.gov.
Information on this page may relate to penny stocks, which may also be referred to as low-priced stocks. Penny stocks are low-priced shares typically issued by small companies. Penny stocks involve greater than normal risk, they may be less liquid than other stocks (i.e., more difficult to sell), and there may be less reliable information available regarding such stocks. Investors in penny stocks should be prepared for the possibility that they may lose their entire investment.
B2I DIGITAL, Inc. is a marketing sponsor of the Roth 34th Annual Roth Conference. B2I DIGITAL, Inc. is not an affiliate of Roth Capital Partners, LLC (“Roth”) and is not authorized to represent or act on behalf of Roth ,in any capacity. Roth has not reviewed and approved the content contained on the b2idigital.com website.
